So, how do we diagnose diabetes?
So, it’s a serum glucose level
of 126 mg/dL or 7 mmol per liter
on two separate occasions.
And also glucose in the urine can be supportive as well,
but I think really we use serum
markers to identify diabetes.
Or it could be an HbA1c of 6.5% or
more on two separate occasions.
But if a patient comes in with fatigue
and polyuria and polydipsia
and you check their glucose in the clinic
and it's over 200 mg/dL,
no further testing is necessary.
They have diabetes.
Of course, those patients will get a
baseline HbA1c level right away as well.
So, I think this is good for patient care and also
good for what may come up on your exam.
This is the routine evaluation for
patients with diabetes with a schedule.
So, patients with Type II diabetes get their –
an ophthalmologic exam
right away when they're diagnosed
with a dilated pupil for retinal exam.
And then, that's followed at least annually.
The HbA1c, if it’s well-controlled,
can be every six months.
Poorly controlled, every three months.
A complete foot exam with
monofilament testing, at least every year.
Lipids, at least every several years.
I probably draw them more often.
A urine, microalbumin, creatinine ratio at the
time of diagnosis and then annually.
And then blood chemistries and renal
function at least every six months.
All those things fairly straightforward and make sense.
Most of my patients are achieving those goals.
Now, we do an HbA1c level
and it turns out it’s 8.2%.
So, besides lifestyle intervention,
what's the best treatment to prescribe for this patient now?
Is it, A, glipizide; B, Liraglutide;
C, a basal insulin at night; or D, metformin?
And in previous years, you can make an
argument as to which one might be better.
Now, it's fairly clear
and the American Diabetes Association recommends,
along with the American Association of Clinical Endocrinologists,
metformin as a foundational drug for diabetes.
So, we’ll talk about different interventions
for diabetes with medicines in a second,
but you always start with lifestyle first because,
just think about it, a multidisciplinary team
can promote weight loss of up to 9%
among patients with diabetes,
and that's going to reduce
the need to use anti-diabetes drugs
and anti-hypertensive drugs as well.
Physical activity is about as good
as one of the weaker oral agents
for reducing HbA1c.
And diet advice is similar.
It can reduce the HbA1c by another
0.5% to 1% for most people.
And it probably is better when it comes from
somebody with experience in counseling patients,
like a dietitian or a certified diabetes
educator versus a physician
who is trying to manage 20 things at once.
A little pearl regarding home glucose testing,
we recommend this broadly and
probably a little too broadly.
Just in terms of stewardship of resources,
because it can get expensive to get
new machines, to get the lancets,
to get the test strips,
it’s most helpful for patients with severe
diabetes who are taking insulin.
It hasn't really been shown to make
much of a difference among patients
who are fairly well controlled on oral medications,
especially those early in their illness
and it doesn't necessarily change quality-of-life.
Where I might use it in a patient who is on
oral medications alone are patients with
highly fluctuating glucose going very high
and then at risk of hypoglycemia
or for somebody who's chugging
along and taking only Metformin
and their HbA1c is 6.8% to 6.6%
every time I check it.
There's not really much of a need to
do any home glucose testing at all.
So, something to think about.
And I mentioned metformin is the first-line agent.
Why? There's a low risk of hypoglycemia.
Hypoglycemia and its danger has become a lot
more apparent over the past few years
and we’ll talk about some agents
that promote low sugar.
It's usually associated with
a very modest weight loss.
It doesn't create the cycle of more weight gain,
therefore, more insulin resistance
and then more need for drugs.
And the big complication with metformin
that everybody worries about is lactic acidosis.
And it’s more common among
patients with severe kidney disease.
But now, the new rules and
warnings on the drug
state that it can be used for certain patients all the way
down to a glomerular filtration rate of 30 mm/m.
So, that’s kind of remarkable and a big change,
getting metformin to more patients who need it.
Sulfonylureas have been around a long time.
Like metformin, they’re inexpensive.
And like Metformin, they promote about
the same degree of HbA1c reduction.
If you ever get stopped and
have to answer in like half a second,
okay, how much does this drug
reduce – this oral drug reduce HbA1c?
1% is always a good answer
because they tend to be around that level.
But the problem with sulfonylureas
is they can promote hypoglycemia
and weight gain, and
therefore, are maybe less favored.
There’s also an unknown effect
whether they improve mortality or not.
Newer agents now.
Dipeptidyl peptidase-4 inhibitors.
These are – I think the benefit to these drugs is they’re
really well-tolerated and they’re fairly easy to use.
Don’t promote a lot of hypoglycemia.
Low rate of side effects overall.
They can even be used in
moderate renal dysfunction as well.
The drawback, they're not that effective.
So, they're good for patients who are right next to
gold maybe with metformin, but can't quite get there,
but they also have intolerance to multiple drugs.
A DPP-4 inhibitor could be a good idea for them.
only rosiglitazone is available in the United States.
These drugs can promote weight gain,
which is partly water weight.
They can promote edema.
Patients with a history of bladder cancer or
osteoporosis should not be using these drugs.
And they reduce HbA1c by about 1%.
So, these still have some role,
but it's probably a more limited secondary role in the
management of most cases of Type II diabetes.
What about the glucagon-like
peptide-1 receptor agonists?
So, these are different drugs.
These are again even a newer wave.
They've been out for several years now.
So, it's important for us to know them.
Different dosing schedules, but they are
not – there is no oral product out there right now.
There are subcutaneous injections.
They rarely are associated with pancreatitis
and you can’t use them on
patients with the most severe
chronic kidney disease, but they can
be used in moderate kidney disease.
The beneficial effects of GLP-1 agonists,
they can promote weight loss.
Sometimes, it exceeds 6 or 7 kg.
Routinely, it's going to be at least 4 kg.
So, weight loss is important.
It's something that patients can really hold on to.
It's not easy to lose 4 kg of
body weight for many patients.
And their HbA1c action is a little
bit stronger than other oral agents.
So, between the fact that
it promotes weight loss
and it reduces A1c fairly robustly,
I like GLP-1 agonists.
Another new kid on the block,
the sodium-glucose cotransporter-2,
or SGLT2 inhibitors,
these inhibit glucose reuptake.
They work in the kidneys.
They have been associated with a higher
risk for UTI as well as genital fungal infections.
These also promote weight loss though,
as well as they lower blood pressure
in and of themselves too.
Again, a little bit weaker though
for their HbA1c reduction.
So, not something – not that strong reduction you
might experience with a GLP-1 agonist.